Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.

Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrhino F, Green AI, Glick IB, Kahn RS, Sharma T, Tohen M, McEvoy JP, Weiden PJ, Lieberman JA; HGDH Research Group.

Schizophr Res. 2006 Mar;83(1):53-63. Epub 2006 Mar 9.

PMID:
16529910
2.

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.

Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA.

Am J Psychiatry. 2004 Jun;161(6):985-95.

PMID:
15169686
3.
4.

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.

Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM; HGDH Study Group.

Am J Psychiatry. 2003 Aug;160(8):1396-404.

PMID:
12900300
5.

Olanzapine versus haloperidol treatment in first-episode psychosis.

Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr, Tollefson GD.

Am J Psychiatry. 1999 Jan;156(1):79-87.

PMID:
9892301
6.
7.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
8.

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.

Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE; EUFEST study group.

Lancet. 2008 Mar 29;371(9618):1085-97. doi: 10.1016/S0140-6736(08)60486-9.

PMID:
18374841
9.

Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).

Volavka J, Czobor P, Derks EM, Bitter I, Libiger J, Kahn RS, Fleischhacker WW; EUFEST Study Group.

J Clin Psychiatry. 2011 Jul;72(7):955-61. doi: 10.4088/JCP.10m06529.

PMID:
21824456
10.

Olanzapine and haloperidol in first episode psychosis: two-year data.

Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB; HGDH Study Group.

Schizophr Res. 2006 Sep;86(1-3):234-43. Epub 2006 Aug 2.

PMID:
16887334
11.

Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.

Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, Chakos M, McEvoy JP.

J Clin Psychiatry. 2002 Oct;63(10):931-5.

PMID:
12416603
12.

Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.

Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB.

Arch Gen Psychiatry. 2006 Jun;63(6):622-9.

PMID:
16754835
13.
14.

Atypical antipsychotics for psychosis in adolescents.

Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS.

Cochrane Database Syst Rev. 2013 Oct 15;(10):CD009582. doi: 10.1002/14651858.CD009582.pub2. Review.

PMID:
24129841
15.

Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.

Dossenbach M, Pecenak J, Szulc A, Irimia V, Anders M, Logozar-Perkovic D, Peciukaitiene D, Kotler M, Smulevich AB, West TM, Lowry AJ, Treuer T.

J Clin Psychiatry. 2008 Dec;69(12):1901-15. Epub 2008 Sep 9.

PMID:
19012820
16.

A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.

Crespo-Facorro B, Pérez-Iglesias R, Ramirez-Bonilla M, Martínez-García O, Llorca J, Luis Vázquez-Barquero J.

J Clin Psychiatry. 2006 Oct;67(10):1511-21.

PMID:
17107241
17.

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.

PMID:
19167596
18.

First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.

Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS; HGDH Research Group.

Schizophr Res. 2004 Feb 1;66(2-3):125-35.

PMID:
15061244
19.

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.

Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME.

Am J Psychiatry. 1997 Apr;154(4):457-65.

PMID:
9090331
20.

Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.

Strassnig M, Miewald J, Keshavan M, Ganguli R.

Schizophr Res. 2007 Jul;93(1-3):90-8. Epub 2007 May 2.

Supplemental Content

Support Center